GTC Expands Portfolio to Include Proteins Produced in Pig's Milk
Under a new agreement with ProGenetics LLC (Blacksburg, VA), GTC Biotherapeutics (GTC, Framingham, MA) will expand its portfolio to include protein therapeutics produced in the milk of transgenic pigs.
Under a new agreement with ProGenetics LLC (Blacksburg, VA), GTC Biotherapeutics (GTC, Framingham, MA) will expand its portfolio to include protein therapeutics produced in the milk of transgenic pigs. GTC currently produces and markets ATryn, a recombinant form of human antithrombin, produced in the milk of transgenic goats.
The agreement grants GTC an exclusive license to develop and commercialize ProGenetics’ recombinant human factor IX, recombinant human factor VIII, and recombinant human fibrinogen for North America, Europe, and Japan. ProGenetics will be responsible for the production of the proteins in the milk of their transgenic pigs. GTC will be responsible for manufacturing, clinical development, regulatory affairs, and commercialization activities in its territories.
In exchange, ProGenetics will receive a non-exclusive license to GTC’s patent in the US for the transgenic expression of therapeutic proteins in milk to enable the commercial development of these products outside of North America, Europe, and Japan.
GTC was the first company to receive approval anywhere in the world for a transgenically produced protein for human therapeutic use when it received European Commission approval for ATryn in August 2006. The company plans to submit a biologics license application in the US in the first half of 2008.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
